GERD AND MANAGEMENT MODALITIES

Authors

  • Mohamed Mostafa International students faculty, Asia International University, Bukhara

DOI:

https://doi.org/10.55640/

Keywords:

GERD, PPIs, PPI-refractory GERD, P-CABs, LES, esophageal motility, refractory GERD, long-term relief, quality of life, vonoprazan, tegoprazan, fexuprazan

Abstract

Gastroesophageal reflux disease (GERD) is a chronic disorder resulting from the retrograde flow of gastric contents into the esophagus, leading to a spectrum of complications that adversely affect quality of life, increase morbidity, and impose substantial healthcare costs. The primary therapeutic objectives in GERD management are the alleviation of symptoms, prevention of recurrence, and promotion of mucosal healing in erosive esophagitis. First-line therapy typically consists of lifestyle modifications aimed at reducing gastric acid exposure, in conjunction with proton pump inhibitors (PPIs) to suppress acid secretion. For patients with persistent or refractory symptoms, despite optimized medical therapy, endoscopic techniques or surgical interventions such as anti-reflux procedures may provide symptomatic relief and improved disease control. This review will address the underlying pathophysiology of GERD, advances in diagnostic modalities, and contemporary therapeutic strategies, including surgical options for the management of refractory disease.

Downloads

Download data is not yet available.

References

1.Katz, P. O., Gerson, L. B., & Vela, M. F. (2013). Guidelines for the diagnosis and management of gastroesophageal reflux disease. The American Journal of Gastroenterology, 108(3), 308–328. (doi.org in Bing)

2.Vakil, N., van Zanten, S. V., Kahrilas, P., Dent, J., & Jones, R. (2006). The Montreal definition and classification of gastroesophageal reflux disease: A global evidence-based consensus. The American Journal of Gastroenterology, 101(8), 1900–1920. (doi.org in Bing)

3.Scarpignato, C., Gatta, L., Zullo, A., & Blandizzi, C. (2016). Effective and safe proton pump inhibitor therapy in acid-related diseases – A position paper addressing benefits and potential harms of acid suppression. BMC Medicine, 14(1), 179. (doi.org in Bing)

4.Ashida, K., Sakurai, Y., Nishimura, A., Kudou, K., Hiramatsu, N., & Umegaki, E. (2016). Randomised clinical trial: Efficacy and safety of vonoprazan versus lansoprazole in patients with erosive oesophagitis. Alimentary Pharmacology & Therapeutics, 43(2), 240–251. https://doi.org/10.1111/apt.13466

5.Kahrilas, P. J., & Boeckxstaens, G. (2016). Failure of reflux inhibitors in clinical trials: Lessons for future development. Journal of Neurogastroenterology and Motility, 22(4), 509–516. https://doi.org/10.5056/jnm16094

6.Shaheen, N. J., & Richter, J. E. (2009). Barrett’s esophagus. The Lancet, 373(9666), 850–861. (doi.org in Bing)

7.El-Serag, H. B., Sweet, S., Winchester, C. C., & Dent, J. (2014). Update on the epidemiology of gastro-oesophageal reflux disease: A systematic review. Gut, 63(6), 871–880. (doi.org in Bing)

8.Gyawali, C. P., Kahrilas, P. J., Savarino, E., Zerbib, F., Mion, F., Smout, A. J., ... & Sifrim, D. (2018). Modern diagnosis of GERD: The Lyon Consensus. Gut, 67(7), 1351–1362. (doi.org in Bing)

Downloads

Published

2026-03-21

How to Cite

GERD AND MANAGEMENT MODALITIES. (2026). Journal of Multidisciplinary Sciences and Innovations, 5(03), 1621-1624. https://doi.org/10.55640/

Similar Articles

1-10 of 1529

You may also start an advanced similarity search for this article.